Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

5 February 2026 Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.

Europe

Drowning in EU regulations? Five tips for surviving the deluge of new rules

3 February 2026 As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

More features

Novartis takes aim at Tafinlar generic in latest suit

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Moderna VP and regulatory expert moves to private practice

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Fed Circ overturns PTAB decision in $83.4m DNA case

AI is transforming top 100 innovators, shows index

Are the Broad Institute’s CRISPR patents too broad?

More on this story

Editor's picks

Editor's picks

More features